Trial intelligence / Profile preview

PURETHAL Mites rush versus conventional up-dosing safety study in adults with house dust mite allergic rhinitis/rhinoconjunctivitis

2026-526908-72-00Phase 2Authorised

Sponsor: HAL Allergy Group
Start: Oct 2026
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries: 2

Overview

Phase 2, randomised, open-label trial of Purethal in house dust mite allergic rhinitis, allergic rhinoconjunctivitis (ARC) and asthma (2 arms), sponsored by HAL Allergy Group. Planned start Oct 2026; status: authorised.

Drugs

Purethal

Conditions

house dust mite allergic rhinitisallergic rhinoconjunctivitis (ARC)asthma

Beyond the preview

Go deeper on 2026-526908-72-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-526908-72-00.